SUBSCRIBE
SUBSCRIBE
News   Drug Development

Innate Therapeutics Initiates Phase 2 Testing of MIS416 in Patients With Progressive Multiple Sclerosis

October 11, 2010 | 
1 min read

AUCKLAND, New Zealand--(BUSINESS WIRE)--Innate Therapeutics today announced that the company has begun treating patients in a Phase 2a clinical study of its lead molecule, MIS416, in patients with progressive multiple sclerosis (MS).

Clinical research Phase II Europe Australia
MORE ON THIS TOPIC
Pictured: Boehringer Ingelheim sign on a building/
Schizophrenia
Boehringer Suffers Phase III Schizophrenia Fail, Legal Parry by HHS
January 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Businessman jump careful on cracked or broken graph. Job opportunity and career. concept of under pressure. risk, financial, and tax
Pipeline
New Safety Signals Force Keros to Fully Terminate Mid-Stage PAH Study
January 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Business
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
January 15, 2025
 · 
1 min read
 · 
Heather McKenzie
Pictured: A sign on a J.P. Morgan building in Hong Kong/iStock, danielvfung
Pipeline
JPM25 Day One: Pfizer, BioNTech, Moderna and More Present Pipeline Updates
January 14, 2025
 · 
3 min read
 · 
Dan Samorodnitsky